Last reviewed · How we verify
NCT06556953
Evaluating the Risk of Postoperative Venous Thromboembolism in Cervical Cancer Patients
trial in Venous Thromboembolism in 1,174 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | Haike Lei |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,174 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Conditions studied
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
Haike Lei
Who can join
Adults 20 to 89, female only, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to develop a machine learning model to accurately predict the risk of venous thromboembolism in patients with cervical cancer after surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06556953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Venous Thromboembolism
Currently open trials in the same condition.
- NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
- NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
- NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting
Other Haike Lei trials
Trials by the same sponsor.
- NCT06550739 — Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06556953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haike Lei
- Last refreshed: 16 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06556953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing